| Document Date: 2013-10-09 11:18:07
Open Document File Size: 150,37 KBShare Result on Facebook
City MONTREAL / / Company BDC Capital / Alethia Biotherapeutics Inc. / Go Capital / / Country United States / / / Event Patent Issuance / Funding / / IndustryTerm discovery technology / stage biotechnology / monoclonal antibody therapeutics / biotechnology / / MedicalCondition bone resorption / / Organization AgeChem Venture Fund / / Person Mario Filion / Yves Cornellier / / / Position Chief Scientific Officer / VP / CSO mariof@alethiabio.com Tel / President & CEO / Executive VP / President and CEO / / Product Series A / / Technology STAR discovery technology / Antibodies / biotechnology / using its patented STAR discovery technology / /
SocialTag |
Alethia Biotherapeutics Announces the Issuance of a Patent for the Use of Anti-Siglec-15 Antibodies MONTREAL, October 9, 2013 – Alethia Biotherapeutics Inc., a privately held biotechnology company, announced today that